Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MYGN vs IMDX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MYGN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–2 Matrix Metrics)

MYGN Overall Winner 6-Pillar Tally: MYGN 6 – 0 IMDX Matrix Metrics: MYGN 7 – 2 IMDX

As of Nov 19, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYGN carries a Unified Composite Score of 45.4/100 (HOLD) at $5.54 (54.0x Forward P/E, -13.3% operating margin), whereas IMDX carries 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin).

  • Growth vs. Quality Trade-Off: MYGN earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. IMDX 45.5/100 HOLD) and 0.63β · 54% Vol risk profile, whereas IMDX leads top-line expansion (+115.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MYGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4); meanwhile IMDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYGN vs IMDX
MYGN NASDAQ Head-to-Head Winner
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.54
+0.18% 1D
Market Cap $530.4M
TTM Revenue $804M
Forward P/E 54.0x
Beta / 30D Vol 0.63β · 54% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 42.0 Fund 48.0 Flow 59.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (28.9% over 20 days), RSI 51
RSI-14: 51.4 · SMA20: $5.93 · SMA50: $4.93
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 2.91β · 76% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $2.51 · SMA50: $3.10

6-Pillar Scorecard Institutional Category Breakdown (MYGN 6 – 0 IMDX)

Columns: Metric · MYGN · IMDX
1. Valuation Multiples MYGN
Forward P/E 54.0x N/M
Trailing P/E 54.0x N/M
PEG Ratio 1.40x N/M
EV / Revenue 0.8x 18.8x
2. Growth & Scale MYGN
Revenue Growth (YoY) -1.5% +115.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $804M $2.0M
Market Cap $530.4M $52.1M
3. Profitability & Quality MYGN
Gross Margin 68.3% 55.6%
Operating Margin -13.3% -1883.2%
Net Profit Margin -16.1% 0.0%
Return on Equity (ROE) -40.2% -23603.1%
4. Balance Sheet & Cash Flow MYGN
Cash Generation (TTM) -$38M -$31M
Cash Flow Margin -4.7% N/A
Net Cash / Leverage $102M Net Debt (0.78x D/E) $15M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYGN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 124.6% (22nd %ile) 99.4% (12th %ile)
Put/Call OI Skew 0.08x (Call-Skewed) 0.08x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MYGN
OpEx & R&D Intensity 81.6% of Rev ($656M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYGN (7) vs IMDX (2)
Institutional Metric MYGN IMDX Criterion Row Edge
Market Capitalization
Scale
$530.4M $52.1M Larger Scale MYGN
Trailing P/E Ratio
Valuation
54.0x N/M Lower Multiple MYGN
Forward P/E Ratio
Valuation
54.0x N/M Lower Multiple MYGN
Revenue Growth (YoY)
Growth
-1.5% +115.0% Higher Growth IMDX
Operating Margin (TTM)
Profitability
-13.3% -1883.2% Higher Margin MYGN
Net Profit Margin
Profitability
-16.1% 0.0% Higher Margin IMDX
Return on Equity (ROE)
Capital Efficiency
-40.2% -23603.1% Higher ROE MYGN
52-Week Range Position
Momentum
52% ($3–$8) 3% ($2–$8) Stronger Trend MYGN
Beta / 30D Volatility
Risk Regime
0.63β · 54% Vol 2.91β · 76% Vol Lower Realized Risk MYGN
Unified Institutional Score
Composite Signal
45.4 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$804M $2.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.3% 55.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.40x PEG · 0.8x EV/Rev N/M PEG · 18.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$38M ($102M Net Debt (0.78x D/E)) -$31M ($15M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYGN +44.49 pp
MYGN: -0.54% · IMDX: -45.03%
3M Horizon MYGN +134.87 pp
MYGN: +73.12% · IMDX: -61.75%
6M Horizon MYGN +113.46 pp
MYGN: +41.69% · IMDX: -71.77%
1Y Horizon MYGN +57.34 pp
MYGN: -16.44% · IMDX: -73.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MYGN Revenue IMDX Revenue MYGN Op. Margin IMDX Op. Margin Margin Leader
FY2018 $740M N/A 16.4% N/A MYGN
FY2019 $850M N/A 0.9% N/A MYGN
FY2020 $560M $0M -52.0% -2443.3% MYGN
FY2021 $690M $0M -27.6% -2444.3% MYGN
FY2022 $680M $0M -20.7% -1878.6% MYGN
FY2023 $750M $0M -34.2% -1672.4% MYGN
FY2024 $840M $0M -14.7% -3245.1% MYGN
FY2025 $820M $0M -47.0% -1260.8% MYGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYGN CONSOLIDATION
15d in phase · OBV DISTRIBUTION
Current IV 124.6%
IV Percentile 22nd %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MYGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMDX BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 99.4%
IV Percentile 12th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IMDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYGN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $530.4M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment 81.6% of Rev ($656M)
90D Engineering Disclosures 0 Published
IMDX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $52.1M market capitalization and -1883.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MYGN vs IMDX Key Questions & Quantitative Answers

As of Nov 19, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYGN carries a Unified Composite Score of 45.4/100 (HOLD) at $5.54 (54.0x Forward P/E, -13.3% operating margin), whereas IMDX carries 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin). Growth vs. Quality Trade-Off: MYGN earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. IMDX 45.5/100 HOLD) and 0.63β · 54% Vol risk profile, whereas IMDX leads top-line expansion (+115.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MYGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4); meanwhile IMDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYGN leads the Growth & Scale pillar: MYGN posts -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin), compared with IMDX at +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYGN cumulative revenue shifted +10.8% while IMDX shifted N/A. In operating R&D and SG&A reinvestment, MYGN deploys 81.6% of Rev ($656M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMDX.

MYGN screens cheaper on headline valuation multiples. MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin), whereas IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYGN (-40.2% ROE) versus IMDX (-23603.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.63β · 54% Vol realized risk). By comparison, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.